Sponsors (6)
The bill broadens access to lower‑cost, FDA‑approved medicines from certified foreign sources with testing and oversight to improve affordability and access, but it increases regulatory and enforcement burdens, poses safety and supply‑chain risks if controls fail, and may pressure domestic manufacturers and some businesses.
Low‑ and moderate‑income people, uninsured patients, and those who pay high drug costs (including insulin users and many with chronic conditions) can buy approved medicines from certified foreign sellers at lower prices, reducing out‑of‑pocket spending.
Patients who currently skip or delay filling prescriptions because of cost (including many Medicare and Medicaid beneficiaries) are more likely to get needed medicines, which can improve health outcomes.
Public reporting, laboratory testing/certification requirements, Secretary suspension authority, and GAO oversight provide transparency and accountability that help detect and respond to safety problems and allow monitoring of program performance.
Patients (including Medicare beneficiaries and others with chronic conditions) face a risk that counterfeit, adulterated, or diverted drugs could reach the U.S. supply if certification, testing, or supply‑chain controls fail.
Taxpayers, HHS, and small pharmacies could bear higher regulatory, inspection, and program administration costs (including certification fees and expanded enforcement), and some of these costs may be passed on to consumers.
U.S. manufacturers and the domestic pharmaceutical workforce may face competitive pressure and incentive to change distribution or pricing strategies, which could reduce domestic investment or jobs and risk supply disruptions in some U.S. channels.
Based on analysis of 3 sections of legislative text.
Introduced May 1, 2025 by Janice D. Schakowsky · Last progress May 1, 2025
Allows regulated importation of many prescription drugs and certain biologics from approved foreign pharmacies and wholesale distributors in Canada, the United Kingdom, EU member states, and Switzerland (with a process to add others). Creates a certification system for foreign sellers and importers, supply‑chain controls, reporting and testing requirements, prohibitions on discriminatory manufacturer behavior, and deadlines for HHS to issue implementing rules and periodic reports. Requires the Department of Health and Human Services (HHS)/FDA to publish a list of certified foreign sellers, approve laboratories for testing, set fees and recertification, and suspend importation when safety or noncompliance risks are found; excludes controlled substances, some anesthetics, and compounded drugs, and includes reporting and GAO oversight requirements after regulations are final.